ETOPOPHOS PRESERVATIVE FREE
Details
- Status
- Prescription
- First Approved
- 1996-05-17
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
ETOPOPHOS PRESERVATIVE FREE Approval History
What ETOPOPHOS PRESERVATIVE FREE Treats
2 indicationsETOPOPHOS PRESERVATIVE FREE is approved for 2 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Testicular Cancer
- Small Cell Lung Cancer
Drugs Similar to ETOPOPHOS PRESERVATIVE FREE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ETOPOPHOS PRESERVATIVE FREE FDA Label Details
ProIndications & Usage
FDA Label (PDF)ETOPOPHOS is a topoisomerase inhibitor indicated for the treatment of patients with: Refractory testicular tumors, in combination with other chemotherapeutic drugs. Small cell lung cancer, in combination with cisplatin, as first-line treatment. 1.1 Refractory Testicular Tumors ETOPOPHOS is indicated, in combination with other chemotherapeutic drugs, for treatment of patients with refractory testicular tumors. 1.2 Small Cell Lung Cancer ETOPOPHOS is indicated, in combination with cisplatin, for first-line treatment of patients with small cell lung cancer.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.